Patents by Inventor Torben Lebmann

Torben Lebmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEGylated Recombinant Human Growth Hormone Compounds
    Patent number: 10098930
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: October 16, 2018
    Assignee: Ascendis Pharma Endocrinology Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • PEGylated Recombinant Human Growth Hormone Compounds
    Publication number: 20160206702
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Application
    Filed: January 19, 2016
    Publication date: July 21, 2016
    Applicant: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • PEGylated recombinant human growth hormone compounds
    Patent number: 9272048
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: March 1, 2016
    Assignee: Ascendis Pharma Growth Disorders Division A/S
    Inventors: Harald Rau, Susanne Kinderman, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
  • PRODRUGS OF HYDROXYL-COMPRISING DRUGS
    Publication number: 20150087688
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a biologically active moiety-linker conjugate D-L, wherein D is a hydroxyl-comprising biologically active moiety; and L is a promoiety comprising a moiety L1 represented by formula (I) and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer and Z is a carrier group. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
    Type: Application
    Filed: April 24, 2013
    Publication date: March 26, 2015
    Inventors: Ulrich Hersel, Torben Lebmann, Harald Rau
  • PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS
    Publication number: 20110112021
    Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
    Type: Application
    Filed: April 29, 2009
    Publication date: May 12, 2011
    Applicant: Ascendis Pharma AS
    Inventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe